Delivery Order SPE2DB20D3505-SPE2DB25FV1N6
- Not listed
- The Defense Logistics Agency awarded a $16,998.05 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery is scheduled to occur at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $23,540.52 on August 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units), with an ultimate completion date of August 19, 2025. This non-competitive, firm fixed-price delivery order will be fulfilled from the vendor's place of performance in Conshohocken, Pennsylvania. The award represents a child order issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $10,146.21 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed price, non-set-aside contract with performance occurring at the contractor's Conshohocken, Pennsylvania facility. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $4,630.35 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed price delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $61,412.92. This competitively awarded, non-set-aside contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The place of performance is located in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a $5,128.38 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This is a firm fixed price, non-set-aside contract with a completion date of July 23, 2025, and performance location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order valued at $15,385.14 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 29, 2025, with an ultimate completion date of September 2, 2025. This non-competitive, firm fixed-price delivery order will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal...
- The Defense Logistics Agency awarded a $22,077.35 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 18, 2025, with a completion date of August 19, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB25FV1N6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,399.71 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 8, 2025, with an ultimate completion date of August 11, 2025. This non-competitive delivery order utilizes firm fixed price terms and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive pharmaceutical supply vehicle for military healthcare systems globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains significant federal contracting relationships with the Defense Logistics Agency and serves critical medical supply needs across the Defense Health Agency and other government healthcare systems. Dupixent is a specialty biologic medication commonly used for moderate-to-severe eczema, asthma, and chronic rhinosinusitis, reflecting the contractor's role in supplying brand-name specialty pharmaceuticals to support military and veteran healthcare programs. The competitively awarded master contract demonstrates the contractor's capability to fulfill diverse federal medical procurement requirements through flexible delivery order mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.4k | 8/8/25 |